

AUTHOR INDEX FOR VOLUME 32

A

- Abel, P. W., *see* Han, C., 505
 Ahljianian, M. K., and Cooper, D. M. F. Calmodulin may play a pivotal role in neurotransmitter-mediated inhibition and stimulation of rat cerebellar adenylate cyclase, 127
 Aiyar, N., Nambi, P., Stassen, F., and Crooke, S. T. Solubilization and reconstitution of vasopressin V₁ receptors of rat liver, 34
 Ajmera, S., *see* Maybaum, J., 606
 Akera, T., *see* Coughlin, R. T., 147
 Akera, T., *see* Ng, Y.-C., 201
 Ambler, S. K., Thompson, B., Soliski, P. A., Brown, J. H., and Taylor, P. Receptor-mediated inositol phosphate formation in relation to calcium mobilization: A comparison of two cell lines, 376
 Ames, M. M., *see* Campbell, N. R. C., 813
 Amitai, G., Herz, J. M., Bruckstein, R., and Luz-Chapman, S. The muscarinic antagonists apophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor, 678
 Anders, M. V., *see* Lash, L. H., 549
 Attisano, C., *see* Waxman, D. J., 615
 Aumelas, A., *see* Jard, S., 369
 Ayusawa, D., *see* Balzarini, J., 410

B

- Bainson, A. N., *see* Maybaum, J., 606
 Balzarini, J., Cooney, D. A., Dalal, M., Kang, G.-J., Cupp, J. E., De Clercq, E., Broder, S., and Johns, D. G. 2',3'-dideoxycytidine: Regulation of its metabolism and antiretroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis, 798
 Balzarini, J., De Clercq, E., Verbruggen, A., Ayusawa, D., Shimizu, K., and Seno, T. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene, 410
 Balzarini, J., Kang, G.-J., Dalal, M., Herdewijn, P., De Clercq, E., Broder, S., and Johns, D. G. The anti-HTLV-III (Anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: A comparison with their parental 2',3'-dideoxyribonucleosides, 162
 Bao, Z.-P., *see* Yang, S. K., 73
 Barber, R., Goka, T. J., and Butcher, R. W. Role of high affinity cAMP phosphodiesterase activities in the response of S49 cells to agonists, 753
 Baur, R., *see* Sigel, E., 749
 Beaujouan, J. C., *see* Bergström, L., 764
 Beaumont, A., Hernandez, J.-F., Chaillet, P., Crine, P., and Roques, B. P. Irreversible photolabeling of active site of neutral endopeptidase-24.11 enkephalinase by azidothiorphan and [¹⁴C]-azidothiorphan, 594
 Belinsky, S. A., Kari, F. W., Kauffman, F. C., and Thurman, R. G. Effect of β -naphthoflavone on mitochondrial supply of reducing equivalents for monooxygenation in periportal and pericentral regions of the liver lobule, 315
 Bennett, C. F., Mong, S., Wu, H.-L. W., Clark, M. A., Wheeler, L., and Crooke, S. T. Inhibition of phosphoinositide-specific phospholipase C by manoalide, 587
 Bentrude, W. G., *see* De Clercq, E., 286
 Benz, C., and Santos, G. F. Effects of *cis*- and *trans*-tamoxifen isomers on RNA incorporation of human breast cancer cells, 13
 Béres, J., *see* De Clercq, E., 286
 Berger, K. D., *see* Brown, R. D., 43
 Bergholte, J. M., *see* Okita, R. T., 706
 Bergström, L., Beaujouan, J. C., Torrens, Y., Saffroy, M., Glowinski, J., Lavielle, S., Chassaing, G., Marquet, A., D'Orleans-Juste, P., Dion, S., and Regoli, D. ³H-Neurokinin A labels a specific tachykinin-binding site in the rat duodenal smooth muscle, 764
 Bernaerts, R., *see* Votruba, I., 524
 Birkett, D. J., *see* McManus, M. E., 189
 Blank, J. A., Tucker, A. N., Sweatlock, J., Gasiewicz, T. A., and Luster, M. I. α -Naphthoflavone antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced murine lymphocyte ethoxyresorufin-O-deethylase activity and immunosuppression, 168
 Bock, K. W., *see* Lilienblum, W., 173
 Bockaert, J., *see* Schmidt, B., 364
 Bonner, T. T., *see* Brann, M. R., 450
 Bornheim, L. M., Underwood, M. C., Caldera, P., Rettie, A. E., Trager, W. F., Wrighton, S. A., and Correia, M. A. Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: Mechanistic implications, 299
 Braguer, D., *see* Chaudoreille, M. M., 731
 Brandes, S. J., and Katzenellenbogen, J. A. Fluorinated androgens and progestins: Molecular probes for androgen and progesterone receptors with potential use in positron emission tomography, 391
 Brann, M. R., Buckley, N. J., Jones, S. V. P., and Bonner, T. T. Expression of a cloned muscarinic receptor in A9 L cells, 450
 Brass, E. P., *see* Daniell, L. C., 831
 Braswell, L. M., *see* Dodson, B. A., 119
 Braunwalder, A. F., *see* Loo, P. S., 820
 Brennan, J., *see* McManus, M. E., 189
 Broder, S., *see* Balzarini, J., 162, 798
 Brouwer, K. L. R., Durham, S., and Vore, M. Multiple carriers for uptake of [³H]-estradiol 17 β -(β -D-glucuronide) in isolated rat hepatocytes, 519
 Brown, J. H., *see* Ambler, S. K., 376
 Brown, R. D., Berger, K. D., and Taylor, P. The relationship between α_1 -adrenergic receptor occupancy and response in BC3H-1 muscle cells, 43
 Bruckstein, R., *see* Amitai, G., 678
 Brüne, B., and Ullrich, V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase, 497
 Buckley, N. J., *see* Brann, M. R., 450
 Burgess, W., *see* McManus, M. E., 189
 Butcher, R. W., *see* Barber, R., 753

C

- Caldera, P., *see* Bornheim, L. M., 299
 Campbell, N. R. C., Van Loon, J. A., Sundaram, R. S., Ames, M. M., Hansch, C., and Weinshilboum, R. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates, 813
 Candelore, M. R., *see* Strader, C. D., 179
 Cascio, D., *see* McGrath, M., 600
 Catterall, W. A., *see* Gono, T., 691
 Ceña, V., *see* González-García, C., 792
 Chaillet, P., *see* Beaumont, A., 594
 Chassaing, G., *see* Bergström, L., 764
 Chaudoreille, M. M., Peyrot, V., Braguer, D., and Crevat, A. Interaction of some estrogenic drugs with tubulin. Formation of twisted ribbon structures, 731

- Chen, G.-X., and Zolg, J. W. Purification of the bifunctional thymidylate synthase-dihydrofolate reductase complex from the human malaria parasite *Plasmodium falciparum*, 723
- Cheng, Y.-C., see Townsend, A. J., 330
- Christie, M. J., Williams, J. T., and North, R. A. Cellular mechanisms of opioid tolerance: studies in single brain neurons, 633
- Christophe, J., see Gillard, M., 100
- Christophe, J., see Waelbroeck, M., 91
- Clark, M. A., see Bennett, C. F., 587
- Clark, M. A., see Snyder, R. M., 437
- Claro, E., Garcia, A., and Picatoste, F. Histamine-stimulated phosphoinositide hydrolysis in developing rat brain, 384
- Coleman, B. A., Michel, L., and Oswald, R. Interaction of a benzomorphan opiate with acetylcholinesterase and the nicotinic acetylcholine receptor, 456
- Colucci, W. S., see Sperti, G., 37
- Convents, A., De Backer, J.-P., Convents, D., and Vauquelin, G. Tight agonist binding may prevent the correct interpretation of agonist competition binding curves for α_1 -adrenergic receptors, 65
- Convents, D., see Convents, A., 65
- Cooney, D. A., see Balzarini, J., 798
- Cooper, D. M. F., see Ahljianian, M. K., 127
- Cooper, D. M. F., see Perez-Reyes, E., 212
- C'Orleans-Juste, P., see Bergström, L., 764
- Correia, M. A., see Bornheim, L. M., 299
- Coughlin, R. T., Akera, T., McGroarty, E. J., and Steinbach, C. Ligand effects on membrane lipids associated with sodium, potassium-activated adenosine triphosphatase: Comparative spin probe studies with rat brain and heart enzyme preparations, 147
- Crevat, A., see Chaudoreille, M. M., 731
- Crine, P., see Beaumont, A., 594
- Crooke, S. T., see Aiyar, N., 34
- Crooke, S. T., see Bennett, C. F., 587
- Crooke, S. T., see Mong, S., 223
- Crooke, S. T., see Per, S. R., 17
- Crooke, S. T., see Shorr, R. G. L., 195
- Crooke, S. T., see Snyder, R. M., 437
- Cross, J., see Hait, W. N., 404
- Cupp, J. E., see Balzarini, J., 798
- D**
- Dalal, M., see Balzarini, J., 162, 798
- Daly, J. W., see Gusovsky, F., 479
- Daniell, L. C., Brass, E. P., and Harris, R. A. Effect of ethanol on intracellular ionized calcium concentrations in synaptosomes and hepatocytes, 831
- De Backer, J.-P., see Convents, A., 65
- DeCaprio, A. P., Jackowski, S. J., and Regan, K. A. Mechanism of formation and quantitation of imines, pyrroles, and stable, non-pyrrole adducts in 2,5-hexanedione-treated protein, 542
- De Clercq, E., Bérés, J., and Bentrude, W. G. Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK⁻) herpes simplex virus: Targeted at thymidylate synthase, 286
- De Clercq, E., see Balzarini, J., 162, 410, 798
- De Clercq, E., see Votruba, I., 524
- Dehmel, V. C., see Schimmel, R. J., 26
- De Souza, N. J., see Laurenza, A., 133
- DeWolf, W. E., Jr., see Shorr, R. G. L., 195
- Diamond, J., see MacLeod, K. M., 59
- Dion, S., see Bergström, L., 764
- Dixon, R. A. F., see Strader, C. D., 179
- Dodson, B. A., Braswell, L. M., and Miller, K. W. Barbiturates bind to an allosteric regulatory site on nicotinic acetylcholine receptor-rich membranes, 119
- Drake, F. H., see Per, S. R., 17
- Durham, S., see Brouwer, K. L. R., 519
- Durkin, J. A., see Weiland, G. A., 625
- E**
- Edge, M., see Kemp, G., 356
- Elliott, M. E., see Schimmel, R. J., 26
- F**
- Fallon, R. J., and Schwartz, A. L. Mechanism of the phorbol ester-mediated redistribution of asialoglycoprotein receptor: Selective effects on receptor recycling pathways in hep G2 cells, 348
- Fischmeister, R., see Hartzell, H. C., 639
- Fisher, S. K., and Snider, R. M. Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas, 81
- Friedberg, T., see Steinberg, P., 463
- G**
- Galitzky, J., see Paris, H., 646
- Galper, J. B., Haigh, L. S., Hart, A. C., O'Hara, D. S., and Livingston, D. J. Muscarinic cholinergic receptors in the embryonic chick heart: Interaction of agonist, receptor, and guanine nucleotides studied by an improved assay for direct binding of the muscarinic agonist [³H]cismethyldioxolane, 230
- Garcia, A., see Claro, E., 384
- Gasiewicz, T. A., see Blank, J. A., 168
- Gelboin, H. V., see Waxman, D. J., 615
- Gillard, M., see Waelbroeck, M., 91
- Gillard, M., Waelbroeck, M., and Christophe, J. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled with [³H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists, 100
- Glazer, L., see Hait, W. N., 404
- Gleason, J. G., see Mong, S., 223
- Glover, E., see Poland, A., 471
- Glowinski, J., see Bergström, L., 764
- Goka, T. J., see Barber, R., 753
- Goldfien, A., see Riemer, R. K., 663
- Goldstein, J. A., see Yeowell, H. N., 340
- González-García, C., Ceña, V., and Klein, D. C. Characterization of the α -like Na⁺,K⁺-ATPase which mediates ouabain inhibition of adrenergic induction of N-acetyltransferase (EC 2.3.1.87) activity: Studies with isolated pinealocytes, 792
- Gonoi, T., Ohizumi, Y., Kobayashi, J., Nakamura, H., and Catterall, W. A. Actions of a polypeptide toxin from the marine snail *Conus striatus* on voltage-sensitive sodium channels, 691
- Gotlib, L., see Shorr, R. G. L., 195
- Graham, R. M., see Sawutz, D. G., 565
- Greene, M., see McGrath, M., 600
- Greenlee, D. V., and Okada, S. Calmodulin activates adenylate cyclase from rat anterior pituitary, 743
- Guan, H.-C., see Seeman, P., 760
- Guild, S., see Reisine, T., 488
- Gundlach, A. L., see Largent, B. L., 772
- Gusovsky, F., McNeal, E. T., and Daly, J. W. Stimulation of phosphoinositide breakdown in brain synaptoneuroosomes by agents that activate sodium influx: antagonism by tetrodotoxin, saxitoxin, and cadmium, 479
- H**
- Hagiwara, M., Inagaki, M., Watanabe, M., Ito, M., Onoda, K., Tanaka, T., and Hidaka, H. Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isouquinolinesulfonamide derivatives, 7
- Haigh, L. S., see Galper, J. B., 230
- Hait, W. N., Glazer, L., Kaiser, C., Cross, J., and Kennedy, K. A. Pharmacological properties of fluphenazine-mustard, an irreversible calmodulin antagonist, 404

- Hall, P. de la H., *see* McManus, M. E., 189
Hall, R. F., *see* Mong, S., 223
Han, C., Abel, P. W., and Minneman, K. P. Heterogeneity of α_1 -adrenergic receptors revealed by chlorethylclonidine, 505
Hansch, C., *see* Campbell, N. R. C., 813
Hantelle, P., *see* Kelley, M., 206
Harbon, S., *see* Tanfin, Z., 249
Harden, T. K., *see* Liang, M., 443
Harris, K. H., *see* MacLeod, K. M., 59
Harris, R. A., *see* Daniell, L. C., 831
Harrison, J. H., Jr., and Jollow, D. J. Contribution of aniline metabolites to aniline-induced methemoglobinemia, 423
Hart, A. C., *see* Galper, J. B., 230
Hartzell, H. C., and Fischmeister, R. Effect of forskolin and acetylcholine on calcium current in single isolated cardiac myocytes, 639
Hayes, R., *see* Okita, R. T., 706
Henley, J. M., *see* Weiland, G. A., 625
Herdewijn, P., *see* Balzarini, J., 162
Hernandez, P., *see* Beaumont, A., 594
Herz, J. M., *see* Amitai, G., 678
Hidaka, H., *see* Hagiwara, M., 7
Hirning, L. D., *see* Thayer, S. A., 579
Hoffman, P. L., *see* Valverius, P., 217
Hokin, L. E., *see* Reichman, M., 686
Holý, A., *see* Votruba, I., 524
Honda, A., Mori, Y., Iguchi, K., and Yamada, Y. Antiproliferative and cell cycle effects of newly discovered halogenated coral-prostanoids from the Japanese stolidifer *Clavularia viridis* on human myeloid leukemia cells in culture, 530
Howard, M. J., Hughes, R. J., Motulsky, H. J., Mullen, M. D., and Insel, P. A. Interactions of amiloride with α - and β -adrenergic receptors: Amiloride reveals an allosteric site on α_2 -adrenergic receptors, 53
Howard, M. J., *see* McKernan, R. M., 258
Hughes, R. J., *see* Howard, M. J., 53
- I**
- Iguchi, K., *see* Honda, A., 530
Illas, F., *see* Luque, F. J., 557
Inagaki, M., *see* Hagiwara, M., 7
Insel, P. A., *see* Howard, M. J., 53
Insel, P. A., *see* McKernan, R. M., 258
Ito, M., *see* Hagiwara, M., 7
Iwaniec, L. M., *see* Maybaum, J., 606
- J**
- Jackowski, S. J., *see* DeCaprio, A. P., 542
Jacobson, K. A., *see* Stiles, G. L., 184
Jard, S., Lombard, C., Seyer, R., Aumelas, A., Manning, M., and Sawyer, W. H. Iodination of vasopressin analogues with agonistic and antagonistic properties: Effects on biological properties and affinity for vascular and renal vasopressin receptors, 369
Johns, D. G., *see* Balzarini, J., 162, 798
Johnson, D., *see* McGrath, M., 600
Johnson, R. K., *see* Per, S. R., 17
Jollow, D. J., *see* Harrison, J. H., Jr., 423
Jones, S. V. P., *see* Brann, M. R., 450
Jurd, L., *see* Roach, M. C., 432
- K**
- Kaiser, C., *see* Hait, W. N., 404
Kamp, T. J., and Miller, R. J. Voltage-dependent nitrendipine binding to cardiac sarcolemmal vesicles, 278
Kang, G.-J., *see* Balzarini, J., 162, 798
Kari, F. W., *see* Belinsky, S. A., 315
Katho, A., *see* Nakajima, T., 140
Kato, R., *see* Yamazoe, Y., 536
Katzenellenbogen, J. A., *see* Brandes, S. J., 391
Kauffman, F. C., *see* Belinsky, S. A., 315
Kazmi, S. M. I., and Mishra, R. K. Comparative pharmacological properties and functional coupling of μ and δ opioid receptor sites in human neuroblastoma SH-SY5Y cells, 109
Kelley, M., Hantelle, P., Safe, S., Levin, W., and Thomas, P. E. Co-induction of cytochrome P-450 isozymes in rat liver by 2,4,5,2',4',5'-hexachlorobiphenyl or 3-methoxy-4-aminoazobenzene, 206
Kemp, D. E., *see* Schmidt, B., 364
Kemp, G., and Edge, M. Cholinergic function and α -bungarotoxin binding in PC12 cells, 356
Kennedy, K. A., *see* Hait, W. N., 404
Khandelwal, Y., *see* Laurenza, A., 133
King, A. G., Landreth, K. S., and Wierda, D. Hydroquinone inhibits bone marrow pre-B cell maturation *in vitro*, 807
Kinnier, W. J., *see* Noronha-Blob, L., 669
Klein, D. D., *see* González-García, C., 792
Kobayashi, J., *see* Gonoi, T., 691
Kroll, J. J., *see* Maybaum, J., 606
Kruse, L. I., *see* Shorr, R. G. L., 195
- L**
- Lafranconi, W. M., *see* Steinberg, P., 463
Landreth, K. S., *see* King, A. G., 807
Lanier, S. M., *see* Sawutz, D. G., 565
Lapenson, D. P., *see* Waxman, D. J., 615
Largent, B. L., Wikström, H., Gundlach, A. L., and Snyder, S. H., 000
Lash, L. H., and Anders, M. V. Mechanism of S-(1,2-dichlorovinyl)-L-cysteine- and S-(1,2-dichlorovinyl)-L-homocysteine-induced renal mitochondrial toxicity, 549
Laurenza, A., Khandelwal, Y., De Souza, N. J., Rupp, R. H., Metzger, H., and Seamon, K. B. Stimulation of adenylate cyclase by water-soluble analogues of forskolin, 133
Lavielle, S., *see* Bergström, L., 764
Laychock, S. G. α_2 -Adrenoceptor stimulation affects total glucose utilization in isolated islets of Langerhans, 241
Lehmann, J., *see* Loo, P. S., 820
Levin, W., *see* Kelley, M., 206
Leysen, J. E., *see* Pauwels, P. J., 785
Liang, M., Martin, M. W., and Harden, T. K. [3 H]Propylbenzylcholine mustard-labeling of muscarinic cholinergic receptors that selectively couple to phospholipase C or adenylate cyclase in two cultured cell lines, 443
Liang, M., *see* Toews, M. L., 737
Lilienblum, W., Platt, K. L., Schirmer, G., Oesch, F., and Bock, K. W. Regioselectivity of rat liver microsomal UDP-glucuronosyltransferase activities toward phenols of benzo(a)pyrene and dibenz(a,h)anthracene, 173
Liu-Chen, L.-Y., and Phillips, C. A. Covalent labeling of μ opioid binding site by [3 H] β -funaltrexamine, 321
Livingston, D. J., *see* Galper, J. B., 230
Lombard, C., *see* Jard, S., 369
Lönn, S., *see* Lönn, U., 154
Lönn, U., and Lönn, S. Treatment with dilute alkali-nuclease S₁ permits the analysis of DNA damage: Cells treated with platinum analogues, 154
Loo, P. S., Braunwalder, A. F., Lehmann, J., Williams, M., and Sills, M. A. Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rat brain: Evidence for multiple affinity states of the phencyclidine/N-methyl-D-aspartate receptor complex, 820
Lowe, V. C., *see* Noronha-Blob, L., 669
Lucier, G. W., *see* Sunahara, G. I., 572
Ludena, R. E., *see* Roach, M. C., 432
Luque, F. J., Illas, F., and Pouplana, R. On the mechanism of histamine H₂ receptor activation, 557

Luster, M. I., *see* Blank, J. A., 168
Luz-Chapman, S., *see* Amitai, G., 678

M

MacLeod, K. M., Ng, D. D. W., Harris, K. H., and Diamond, J. Evidence that cGMP is the mediator of endothelium-dependent inhibition of contractile responses of rat arteries to α -adrenoceptor stimulation, 59
Makar, A. B., and Tephly, T. R. The role of formate and S-adenosylmethionine in the reversal of nitrous oxide inhibition of formate oxidation in the rat, 309
Manabe, S., *see* Yamazoe, Y., 536
Manning, D. R., *see* Woolkalis, M. J., 1
Manning, M., *see* Jard, S., 369
Marquet, A., *see* Bergström, L., 764
Martin, M. W., *see* Liang, M., 443
Masters, B. S. S., *see* Okita, R. T., 706
Mattern, M. R., *see* Per, S. R., 17
Maybaum, J., Bainson, A. N., Roethel, W. M., Ajmera, S., Iwaniec, L. M., TerBush, D. R., and Kroll, J. J. Effects of incorporation of 6-thioguanine into SV40 DNA, 606
McGrath, M., Cascio, D., Williams, R., Johnson, D., Greene, M., and McPherson, A. Propidium binding to a ribonuclease-DNA complex: X-ray and fluorescence studies, 600
McGroarty, E. J., *see* Coughlin, R. T., 147
McKernan, R. M., Howard, M. J., Motulsky, H. J., and Insel, P. A. Compartmentation of α_2 -adrenergic receptors in human erythro-leukemia (HEL) cells, 258
McManus, M. E., Hall, P. de la H., Stupans, I., Brennan, J., Burgess, W., Robson, R., and Birkett, D. J. Immunohistochemical localization and quantitation of NADPH-cytochrome P-450 reductase in human liver, 189
McNeal, E. T., *see* Gusovsky, F., 479
McPherson, A., *see* McGrath, M., 600
Merta, A., *see* Votruba, I., 524
Metzger, H., *see* Laurenza, A., 133
Michel, L., *see* Coleman, B. A., 456
Miller, J., *see* Mong, S., 223
Miller, K. W., *see* Dodson, B. A., 119
Miller, R. J., *see* Kamp, T. J., 278
Miller, R. J., *see* Thayer, S. A., 579
Minneman, K. P., *see* Han, C., 505
Minneman, K. P., *see* Nasseri, A., 655
Minnich, M. D., *see* Shorr, R. G. L., 195
Mirabelli, C. K., *see* Per, S. R., 17
Mirabelli, C. K., *see* Snyder, R. M., 437
Mishra, R. K., *see* Kazmi, S. M. I., 109
Mong, S., *see* Bennett, C. F., 587
Mong, S., Wu, H.-L., Miller, J., Hall, R. F., Gleason, J. G., and Crooke, S. T. SKF 104353, a high affinity antagonist for human and guinea pig lung leukotriene D₄ receptor, blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D₄, 223
Mori, Y., *see* Honda, A., 530
Motulsky, H. J., *see* Howard, M. J., 53
Motulsky, H. J., *see* McKernan, R. M., 258
Mullen, M. D., *see* Howard, M. J., 53
Murayama, N., *see* Yamazoe, Y., 536
Murphy, R. C., *see* Okita, R. T., 706

N

Nakajima, T., and Katoh, A. Selective calmodulin inhibition toward myosin light chain kinase by a new cerebral circulation improver Ro 22-4839, 140
Nakamura, H., *see* Gono, T., 691
Nambi, P., *see* Aiyar, N., 34
Nasseri, A., and Minneman, K. P. Relationship between α_2 -adrenergic

receptor binding sites and the functional receptors inhibiting nor-epinephrine release in rat cerebral cortex, 655
Nelson, K. G., *see* Sunahara, G. I., 572
Nen, W., *see* Reichman, M., 686
Ng, D. D. W., *see* MacLeod, K. M., 59
Ng, Y.-C., and Akera, T. Relative abundance of two molecular forms of Na⁺K⁺-ATPase in the ferret heart: Developmental changes and associated alterations of digitalis sensitivity, 201
Noronha-Blob, L., Lowe, V. C., Kinnier, W. J., and U'Prichard, D. C. Heterologous up-regulation of N¹-coupled receptors in cultured neural hybrid cells by a transferable factor, whose expression is inhibited in a cyclic AMP-dependent, cell-specific manner, 669
North, R. A., *see* Christie, M. J., 633

O

Oesch, F., *see* Lilienblum, W., 173
Oesch, F., *see* Steinberg, P., 463
O'Hara, D. S., *see* Galper, J. B., 230
Ohizumi, Y., *see* Gono, T., 691
Okada, S., *see* Greenlee, D. V., 743
Okita, R. T., Soberman, R. J., Bergholte, J. M., Masters, B. S. S., Hayes, R., and Murphy, R. C. ω -Hydroxylation of 15-hydroxyei-cosatetraenoic acid by lung microsomes from pregnant rabbits, 706
Olsen, R. W., *see* Yang, J. S.-J., 266
Onoda, K., *see* Hagiwara, M., 7
Osman, R., Topiol, S., Rubenstein, L., and Weinstein, H. A molecular model for activation of a 5-hydroxytryptamine receptor, 699
Oswald, R., *see* Coleman, B. A., 456

P

Paris, H., Taouis, M., and Galitzky, J. *In vitro* study of α_2 adrenoceptor turnover and metabolism using the adenocarcinoma cell line HT29, 646
Park, S. S., *see* Waxman, D. J., 615
Pauwels, P. J., Van Assouw, H. P., and Leyssen, J. E. Depolarization of chick myotubes triggers the appearance of (+)-[³H]PN 200-110-binding sites, 785
Per, S. R., Mattern, M. R., Mirabelli, C. K., Drake, F. H., Johnson, R. K., and Crooke, S. T. Characterization of a subline of P388 leukemia resistant to amsacrine: Evidence of altered topoisomerase II function, 17
Perez-Reyes, E., and Cooper, D. M. F. Calmodulin stimulation of the rat cerebral cortical adenylate cyclase is required for the detection of guanine nucleotide- or hormone-mediated inhibition, 212
Perkins, J. P., *see* Toews, M. L., 737
Peyrot, V., *see* Chaudoreille, M. M., 731
Phillips, C. A., *see* Liu-Chen, L.-Y., 321
Picatoste, F., *see* Claro, E., 384
Platt, K. L., and Reischmann, I. Regio- and stereoselective metabolism of Dibenz[a,h]anthracene: identification of 12 new microsomal metabolites, 710
Platt, K. L., *see* Lilienblum, W., 173
Poland, A., Glover, E., and Taylor, B. A. The murine Ah locus: A new allele and mapping to chromosome 12, 471
Pouplana, R., *see* Luque, F. J., 557

R

Rands, E., *see* Strader, C. D., 179
Regan, K. A., *see* DeCaprio, A. P., 542
Regoli, D., *see* Bergström, L., 764
Reichman, M., Nen, W., and Hokin, L. E. Effects of Δ^9 -tetrahydrocannabinol on prostaglandin formation in brain, 686
Reischmann, I., *see* Platt, K. L., 710
Reisine, T., and Guild, S. Activators of protein kinase C and cyclic AMP-dependent protein kinase regulate intracellular calcium levels through distinct mechanisms in mouse anterior pituitary tumor cells, 488

- Rettie, A. E., *see* Bornheim, L. M., 299
 Riemer, R. K., Goldfien, A., and Roberts, J. M. Estrogen increases adrenergic- but not cholinergic-mediated production of inositol phosphates in rabbit uterus, 663
 Roach, M. C., Trcka, P. P., Jurd, L., and Luduena, R. E. The effects of 6-benzyl-1,3-benzodioxole derivatives on the alkylation of tubulin, 432
 Robberecht, P., *see* Waelbroeck, M., 91
 Roberts, J. M., *see* Riemer, R. K., 663
 Robson, R., *see* McManus, M. E., 189
 Roethel, W. M., *see* Maybaum, J., 606
 Roques, B. P., *see* Beaumont, A., 594
 Rosenberg, I., *see* Votruba, I., 524
 Rubenstein, L., *see* Osman, R., 699
 Rupp, R. H., *see* Laurenza, A., 133

S

- Safe, S., *see* Kelley, M., 206
 Saffroy, M., *see* Bergström, L., 764
 Sakuma, T., *see* Votruba, I., 524
 Santos, G. F., *see* Benz, C., 13
 Sawutz, D. G., Lanier, S. M., Warren, C. D., and Graham, R. M. Glycosylation of the mammalian α_1 -adrenergic receptor by complex type N-linked oligosaccharides, 565
 Sawyer, W. H., *see* Jard, S., 369
 Schaeffer, V. H., and Stevens, J. L. Mechanism of transport for toxic cysteine conjugates in rat kidney cortex membrane vesicles, 293
 Schimmel, R. J., Elliott, M. E., and Dehmel, V. C. Interactions between adenosine and α_1 -adrenergic agonists in regulation of respiration in hamster brown adipocytes, 26
 Schirmer, G., *see* Lilienblum, W., 173
 Schmidt, B., Weiss, S., Sebben, M., Kemp, D. E., Bockaert, J., and Sladeczek, F. Dual action of excitatory amino acids on the metabolism of inositol phosphates in striatal neurons, 364
 Schwartz, A. L., *see* Fallon, R. J., 348
 Seamon, K. B., *see* Laurenza, A., 133
 Sebben, M., *see* Schmidt, B., 364
 Seeman, P., and Guan, H.-C. Dopamine D₁ and D₂ receptors are sensitive to the cationic form of apomorphine, 760
 Seno, T., *see* Balzarini, J., 410
 Seyer, R., *see* Jard, S., 369
 Shimizu, K., *see* Balzarini, J., 410
 Shorr, R. G. L., Minnich, M. D., Varrichio, A., Strohsacker, M. W., Gotlib, L., Kruse, L. I., DeWolf, W. E., Jr., and Crooke, S. T. Immuno cross-reactivity suggests that catecholamine biosynthesis enzymes and β -adrenergic receptors may be related, 195
 Sigel, E., and Baur, R. Effect of avermectin B_{1a} on chick neuronal γ -aminobutyrate receptor channels expressed in *Xenopus* oocytes, 749
 Sills, M. A., *see* Loo, P. S., 820
 Simasko, S. M., *see* Weiland, G. A., 625
 Sladeczek, F., *see* Schmidt, B., 364
 Smith, C. V. Evidence for participation of lipid peroxidation and iron in diquat-induced hepatic necrosis *in vivo*, 417
 Snider, R. M., *see* Fisher, S. K., 81
 Snyder, R. M., Mirabelli, C. K., Clark, M. A., Ziegler, J. T., and Crooke, S. T. Effect of auranofin and other gold complexes on the activity of phosphodiesterase C, 437
 Snyder, S. H., *see* Largent, B. L., 772
 Soberman, R. J., *see* Okita, R. T., 706
 Solski, P. A., *see* Ambler, S. K., 376
 Sperti, G., and Colucci, W. S. Phorbol ester-stimulated bidirectional transmembrane calcium flux in A_{7r5} vascular smooth muscle cells, 37
 Stassen, F., *see* Aiyar, N., 34
 Steinbach, C., *see* Coughlin, R. T., 147
 Steinberg, P., Lafranconi, W. M., Wolf, C. R., Waxman, D. J., Oesch, F., and Friedberg, T. Xenobiotic metabolizing enzymes are not restricted to parenchymal cells in rat liver, 463
 Stevens, J. L., *see* Schaeffer, V. H., 293
 Stiles, G. L., and Jacobson, K. A. A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity cross-linking probe, 184
 Strader, C. D., Candelore, M. R., Rands, E., and Dixon, R. A. F. β -Adrenergic receptor subtype is an intrinsic property of the receptor gene product, 179
 Strohsacker, M. W., *see* Shorr, R. G. L., 195
 Structural determinants of σ receptor affinity, 000
 Stupans, I., *see* McManus, M. E., 189
 Sunahara, G. I., Nelson, K. G., Wong, T. K., and Lucier, G. W. Decreased human birth weights after *in utero* exposure to PCBs and PCDFs are associated with decreased placental EGF-stimulated receptor autophosphorylation capacity, 572
 Sundaram, R. S., *see* Campbell, N. R. C., 813
 Sweatlock, J., *see* Blank, J. A., 168

T

- Tabakoff, B., *see* Valverius, P., 217
 Takacs, A. L., and Vore, M. Binding of ³H-estradiol-17 β -(β -D-glucuronide), a cholestatic organic anion, to rat liver plasma membranes. Evidence consonant with identification of organic anion carriers, 511
 Tanaka, T., *see* Hagiwara, M., 7
 Tanfin, Z., and Harbon, S. Heterologous regulations of cAMP responses in pregnant rat myometrium evolution from a stimulatory to an inhibitory prostaglandin E₂ and prostacyclin effect, 249
 Taouis, M., *see* Paris, H., 646
 Taylor, B. A., *see* Poland, A., 471
 Taylor, P., *see* Ambler, S. K., 376
 Taylor, P., *see* Brown, R. D., 43
 Tephly, T. R., *see* Makar, A. B., 309
 TerBush, D. R., *see* Maybaum, J., 606
 Thayer, S. A., Hirning, L. D., and Miller, R. J. Distribution of multiple types of Ca²⁺ channels in rat sympathetic neurons *in vitro*, 579
 Thomas, P. E., *see* Kelley, M., 206
 Thompson, B., *see* Ambler, S. K., 376
 Thurman, R. G., *see* Belinsky, S. A., 315
 Toews, M. L., Liang, M., Perkins, J. P. Agonists and phorbol esters desensitize β -adrenergic receptors by different mechanisms, 737
 Topiol, S., *see* Osman, R., 699
 Torrens, Y., *see* Bergström, L., 764
 Townsend, A. J., and Cheng, Y.-C. Sequence-specific effects of ara-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases *in vitro*: Visualization of chain elongation on a defined template, 330
 Trager, W. F., *see* Bornheim, L. M., 299
 Trcka, P. P., *see* Roach, M. C., 432
 Tucker, A. N., *see* Blank, J. A., 168

U

- Ullrich, V., *see* Brüne, B., 497
 Underwood, M. C., *see* Bornheim, L. M., 299
 U'Prichard, D. C., *see* Noronha-Blob, L., 669

V

- Valverius, P., Hoffman, P. L., and Tabakoff, B. Effect of ethanol on mouse cerebral cortical β -adrenergic receptors, 217
 Van Assouw, H. P., *see* Pauwels, P. J., 785
 Van Loon, J. A., *see* Campbell, N. R. C., 813
 Varrichio, A., *see* Shorr, R. G. L., 195
 Vauquelin, G., *see* Convents, A., 65
 Verbruggen, A., *see* Balzarini, J., 410
 Vore, M., *see* Brouwer, K. L. R., 519
 Vore, M., *see* Takacs, A. L., 511

- Votruba, I., Bernaerts, R., Sakuma, T., De Clercq, E., Merta, A., Rosenberg, I., and Holý, A. Intracellular phosphorylation of the broad spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis, 524

W

- Wadhera, A., *see* Yeowell, H. N., 340
Waelbroeck, M., Gillard, M., Robberecht, P., and Christophe, J. Muscarinic receptor heterogeneity in rat central nervous system. I. Binding of four selective antagonists to three muscarinic receptor subclasses: A comparison with M2 cardiac muscarinic receptors of the C type, 91
Waelbroeck, M., *see* Gillard, M., 100
Warren, C. D., *see* Sawutz, D. G., 565
Watanabe, M., *see* Hagiwara, M., 7
Waxman, D. J., Lapenson, D. P., Park, S. S., Attisano, C., and Gelboin, H. V. Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: P-450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations, 615
Waxman, D. J., *see* Steinberg, P., 463
Waxman, D. J., *see* Yeowell, H. N., 340
Weiland, G. A., Durkin, J. A., Henley, J. M., and Simasko, S. M. Effects of substance P on the binding of ligands to nicotinic acetylcholine receptors, 625
Weinshilboum, R., *see* Campbell, N. R. C., 813
Weinstein, H., *see* Osman, R., 699
Weiss, S., *see* Schmidt, B., 364
Wheeler, L., *see* Bennett, C. F., 587
Wierda, D., *see* King, A. G., 807
Wikström, H., *see* Largent, B. L., 772

- Williams, J. T., *see* Christie, M. J., 633
Williams, M., *see* Loo, P. S., 820
Williams, R., *see* McGrath, M., 600
Wolf, C. R., *see* Steinberg, P., 463
Wong, T. K., *see* Sunahara, G. I., 572
Woolkalis, M. J., and Manning, D. R. Structural characteristics of the 35- and 36-kDa forms of the β subunit common to GTP-binding regulatory proteins, 1
Wrighton, S. A., *see* Bornheim, L. M., 299
Wu, H.-L., *see* Mong, S., 223
Wu, H.-L. W., *see* Bennett, C. F., 587

Y

- Yamada, Y., *see* Honda, A., 530
Yamazoe, Y., Manabe, S., Murayama, N., and Kato, R. Regulation of hepatic sulfotransferase catalyzing the activation of *N*-hydroxyarylamide and *N*-hydroxyarylamine by growth hormone, 536
Yang, J. S.-J., and Olsen, R. W. γ -Aminobutyric acid receptor binding in fresh mouse brain membranes at 22°C: Ligand-induced changes in affinity, 266
Yang, S. K., and Bao, Z.-P. Stereoselective formations of K-region and non-K-region epoxides in the metabolism of chrysene by rat liver microsomal cytochrome P-450 isozymes, 73
Yeowell, H. N., Waxman, D. J., Wadhera, A., and Goldstein, J. A. Suppression of the constitutive, male-specific rat hepatic cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene, 340

Z

- Ziegler, J. T., *see* Snyder, R. M., 437
Zolg, J. W., *see* Chen, G.-X., 723

SUBJECT INDEX FOR VOLUME 32

A

- Acetylcholine, forskolin and, calcium current, cardiac myocytes (frog), 639
- Acetylcholinesterase, interaction of benzomorphan opiate, nicotinic acetylcholine receptor (*Torpedo*), 456
- N*-Acetyltransferase, ouabain binding sites, pineal gland (rat), 792
- Acquired immune deficiency syndrome, anti-HTLV-III and cytotoxic activity, 2',3'-didehydro-2',3'-dideoxyribonucleosides, 162
- Adenocarcinoma cells, α -2 adrenoceptor turnover and metabolism, 646
- Adenosine, α_1 -adrenergic agonists and, regulation of respiration, brown adipocytes (hamster), 26
- Adenosine monophosphate, cyclic
- activators of protein kinase C, calcium regulation, anterior pituitary tumor cells (mouse), 488
 - compartmentation, α_2 -adrenergic receptors, human erythroleukemia cells, 258
 - heterologous regulations, pregnant rat myometrium, 249
- N_1 -coupled receptors, heterologous up-regulation, neural hybrid cells, 669
- phosphodiesterase activities, response of S49 cells, agonists, 753
- stimulation of adenylate cyclase, water-soluble analogues, forskolin (rat), 133
- Adenosine triphosphatase, sodium/potassium-activated, ligand effects, membrane lipids (rat), 147
- S*-Adenosylmethionine, formate and, reversal of nitrous oxide inhibition, formate oxidation (rat), 309
- Adenylate cyclase
- calmodulin activation, anterior pituitary (rat), 743
 - cerebellar, calmodulin role, neurotransmitter-mediated inhibition, 127
 - forskolin and acetylcholine effects, cardiac myocytes (frog), 639
 - inhibition, calmodulin, guanine nucleotide, 212
 - muscarinic cholinergic receptors, propylbenzylcholine mustard, 443
 - pregnant rat myometrium, cAMP, heterologous regulations, 249
 - stimulation, water-soluble analogues, forskolin (rat), 133
- Adipocytes, brown, respiration regulation, adenosine and α_1 -adrenergic agonists (hamster), 26
- Adrenoceptors
- alpha*
 - cGMP, endothelium-derived relaxing factors (rat), 59
 - estrogen, inositol phosphate production in uterus (rabbit), 663
 - alpha*-1
 - glycosylation, *N*-linked oligosaccharides, 565
 - heterogeneity, chlorethylclonidine (rat), 505
 - receptor occupancy, BC3H-1 muscle cells, 43
 - alpha*-2
 - compartmentation, human erythroleukemia cells, 258
 - inhibited norepinephrine release, cerebral cortex (rat), 655
 - islet glucose utilization (rat), 241
 - tight agonist binding (calf), 65
 - turnover and metabolism, adenocarcinoma cells, 646
 - alpha* and *beta*, amiloride interactions (rat), 53
 - beta*
 - catecholamine biosynthesis enzymes and, cross reactivity, 195
 - desensitization, agonists and phorbol esters, 737
 - ethanol effect, cerebral cortex (mouse), 217
 - subtype, receptor gene product (mouse), 179
- Adrenocorticotropin, activators of protein kinase C, calcium regulation, anterior pituitary tumor cells (mouse), 488
- Agonists
- binding to muscarinic receptors, cismethyldioxolane, heart (chick), 230
 - histamine H2 receptor activation, mechanism, 557
 - muscarinic receptor heterogeneity, central nervous system (rat), 100
 - phorbol esters and, desensitization, β -adrenergic receptors, 737
 - response of S49 cells, cAMP phosphodiesterase activities, 753
 - tight binding, α_2 -adrenergic receptors (calf), 65
- A9 L cells, expression of cloned muscarinic receptor, 450
- Alkali-nuclease S_1 , analysis of DNA damage, cell treatment, platinum analogues (human), 154
- Alleles, murine *Ah* locus, mapping to chromosome 12 (mouse), 471
- Allylisopropylacetamide, inactivation, multiple hepatic cytochrome P-450 (rat), 299
- N*-Allylnormetazocine, interaction with acetylcholinesterase, nicotinic acetylcholine receptor (*Torpedo*), 456
- Amiloride, interactions with α - and β -adrenergic receptors (rat), 53
- Amino acids, excitatory, metabolism of inositol phosphates, striatal neurons, 364
- γ -Aminobutyric acid
- effect of avermectin B_{1a} , neuronal receptor channels, *Xenopus* oocytes (chick), 749
 - receptor binding, ligand-induced affinity changes, brain (mouse), 266
- 2-Aminophenol, aniline-induced methemoglobinemia (rat), 423
- Aminopyrine *N*-demethylase, activity, parenchymal cells, liver (rat), 463
- Amobarbital, nicotinic acetylcholine-rich membranes, allosteric regulatory site, 119
- Amsacrine, resistance, subline of P388 leukemia, 17
- Analgesia, irreversible photolabeling, enkephalinase, azidothiorphan (mouse), 587
- Androgen
- fluorinated, progestins and, molecular probes for receptors, 391
 - regulation of hepatic sulfotransferase, activation, growth hormone (rat), 536
- Aniline, induced methemoglobinemia, contribution, aniline metabolites (rat), 423
- Anions
- 3H -estradiol-17 β -(β -D-glucuronide)
 - binding to liver plasma membranes (rat), 511
 - multiple carriers for uptake, hepatocytes (rat), 519
- Antagonists, adenosine receptor, radioligand crosslinking probe, 184
- Antiviral activity, 5-fluoro-2'-deoxyuridine, thymidylate synthase, herpes simplex virus, 286
- Apomorphine, cationic form, response, dopamine D_1 and D_2 receptors (dog), 760
- Aprophen, benactyzine and, noncompetitive inhibitors, nicotinic acetylcholine receptor, 678
- 1- β -D-Arabinofuranosyl-5-aza-cytosine, sequence-specific effects, DNA synthesis, DNA polymerases, 330
- Artery, contractile responses, cGMP, α -adrenoceptor stimulation (rat), 59
- Asialoglycoprotein, receptor, phorbol ester-mediated redistribution, 348
- Assays
- agonist competition binding curves, tight agonist binding, α_2 -adrenergic receptors (calf), 65
 - cismethyldioxolane, agonist binding, muscarinic receptors (chick), 230
 - positron emission tomography, fluorinated androgens, progestins, 391

Auranofin, effect on phospholipase C activity, 437
 Avermectin B_{1a}, effect on neuronal γ -aminobutyrate receptor channels, *Xenopus* oocytes (chick), 749
 Azidothiorphan, irreversible photolabeling, enkephalinase (mouse), 587

B

Barbiturates, binding to allosteric regulatory site, nicotinic acetylcholine-rich membranes, 119
 B cells, inhibition of pre-B cell maturation, hydroquinone (mouse), 807
 Benacetyline, apophen and, noncompetitive inhibitors, nicotinic acetylcholine receptor, 678
 Benzene, inhibition of pre-B cell maturation, hydroquinone (mouse), 807
 Benzo(a)pyrene, phenols of, liver microsomal UDP-glucuronosyltransferase, regioselectivity (rat), 173
 Benzomorphinan opiate, interaction with acetylcholinesterase, nicotinic acetylcholine receptor (*Torpedo*), 456
 6-Benzyl-1,3-benzodioxole derivatives, effects on tubulin alkylation, 432
 Bile acid
 ³H-estradiol-17 β -(β -D-glucuronide)
 binding to liver plasma membranes (rat), 511
 multiple carriers for uptake, hepatocytes (rat), 519
 Bisantrene, subline to P388 leukemia, resistance to amsacrine, 17
 Bone marrow, inhibition of pre-B cell maturation, hydroquinone (mouse), 807
 Brain
 development, phosphoinositide hydrolysis, histamine-stimulated (rat), 384
 dopamine D₁ and D₂ receptors, response, cationic form of apomorphine (dog), 760
 effect of ethanol, β -adrenergic receptors (mouse), 217
 ligand effects, sodium/potassium-activated ATPase, membrane lipids (rat), 147
 ligand-induced affinity changes, γ -aminobutyric acid receptor binding (mouse), 266
 muscarinic receptor heterogeneity, central nervous system (rat), 91, 100
 muscarinic receptor reserve, phosphoinositide turnover (guinea pig), 81
 μ opioid binding site, covalent binding, fentanyl (calf), 321
 phencyclidine recognition sites, interaction, L-glutamate and magnesium (rat), 820
 phosphoinositide breakdown of synaptoneurosome, various agents, sodium influx activation (guinea pig), 479
 prostaglandin formation, effects of tetrahydrocannabinol (guinea pig), 686
 single neurons, opioid tolerance, mechanism of (rat), 633
 Breast cancer cells, effects of *cis*- and *trans*-tamoxifen isomers, RNA incorporation (human), 13
 Bromosulphophthalein
 ³H-estradiol-17 β -(β -D-glucuronide)
 binding to liver plasma membranes (rat), 511
 multiple carriers for uptake, hepatocytes (rat), 519
 (E)-5-(2-Bromovinyl)-2'-deoxyuridine, cytostatic activity, thymidylate synthase, mammary carcinoma, 410
 Bromovulone, halogenated coral prostanoids, antiproliferative and cytotoxic effects, leukemia cells, 530
 α -Bungarotoxin, binding in PC12 cells, cholinergic function, 356

C

Cadmium, phosphoinositide breakdown in brain synaptoneurosome, sodium influx activation (guinea pig), 479
 Calcium
 activators of protein kinase C, mechanisms, anterior pituitary tumor cells (mouse), 488
 α_1 -adrenergic receptor occupancy, response, BC3H-1 muscle cells, 43

current, forskolin and acetylcholine effects, cardiac myocytes (frog), 639
 flux, phorbol ester-stimulated, vascular smooth muscle cells (rat), 37
 intracellular ionized concentrates, effect of ethanol, synaptosomes and hepatocytes, 831
 mobilization, inositol phosphate formation, receptor-mediated, 376
 myosin phosphorylation, selective modulation, isoquinolinesulfonamide derivatives (human), 7
 Calcium channels
 distribution of multiple types, sympathetic neurons (rat), 579
 voltage-dependent nitrendipine binding, cardiac sarcolemmal vesicles, 278
 Calmodulin
 activation of adenylate cyclase, anterior pituitary (rat), 743
 inhibition of adenylate cyclase, guanine nucleotide, adenosine receptor, 212
 myosin light chain kinase inhibition, cerebral circulation improver, Ro 22-4839, 140
 neurotransmitter-mediated inhibition, cerebellar adenylate cyclase (rat), 127
 Calmodulin antagonist, fluphenazine-mustard, pharmacological properties, 404
 Camptothecin, subline to P388 leukemia, resistance to amsacrine, 17
 Cannabinoids, prostaglandin formation in brain (guinea pig), 686
 Carbachol, metabolism of inositol phosphates, excitatory amino acids, striatal neurons, 364
 Carbon monoxide, inhibition of platelet aggregation, mediation, guanylate cyclase (human), 497
 Carcinoma, mammary, cytostatic activity, (E)-5-(2-bromovinyl)-2'-deoxyuridine, thymidylate synthase, 410
 Catecholamine, biosynthesis enzymes, β -adrenergic receptors, immuno cross-reactivity, 195
 Cell cycle, halogenated coral prostanoids, antiproliferative and cytotoxic effects, leukemia cells, 530
 Central nervous system, muscarinic receptor heterogeneity (rat), 91, 100
 Cerebral cortex
 β -adrenergic receptors, effect of ethanol (mouse), 217
 heterogeneity of α_1 -adrenergic receptors, chlorethylclonidine (rat), 505
 inhibited norepinephrine release, α_2 -adrenergic receptors (rat), 655
 inhibition of adenylate cyclase, calmodulin, 212
 Chemotherapy, anti-DNA virus agent, intracellular phosphorylation, inhibited viral DNA synthesis, 524
 Chlorethylclonidine, heterogeneity, α_1 -adrenergic receptors (rat), 505
 Chlorovulone, halogenated coral prostanoids, antiproliferative and cytotoxic effects, leukemia cells, 530
 Chromosome 12, murine *Ah* locus, new allele (mouse), 471
 Chrysene, metabolism of, stereoselective formations, K-region and non-K-region epoxides (rat), 73
 Chrysotherapy, effect of auranofin, phospholipase C activity, 437
 Cismethyldioxolane, agonist binding, muscarinic receptors (chick), 230
Clavularia viridis, halogenated coral prostanoids, antiproliferative and cytotoxic effects, leukemia cells, 530
 Clonidine, islet glucose utilization, α_2 -adrenoceptor stimulation (rat), 241
 Colchicine, tubulin alkylation, effects of 6-benzyl-1,3-benzodioxole derivatives, 432
Conus striatus, actions of toxin, voltage-sensitive sodium channels (mouse), 691
 Coral, halogenated prostanoids, antiproliferative and cytotoxic effects, leukemia cells, 530
 Cyclic AMP, *see* Adenosine monophosphate, cyclic
 Cyclic GMP, *see* Guanosine monophosphate, cyclic
 Cycloheximide, α -bungarotoxin binding in PC12 cells, cholinergic function, 356
 Cysteine, transport of toxic conjugates, kidney cortex membrane vesicles (rat), 293

Cytochrome P-450

- co-induction in liver, 2,4,5,2',4',5'-hexachlorobiphenyl, 3-methoxy-4-aminobenzene (rat), 206
 - hepatic, inhibition, monoclonal antibodies (rat), 615
 - φ -hydroxylation of 15-hydroxyeicosanoic acid, lung microsomes, pregnancy (rabbit), 706
 - metabolism of chrysene, K-region and non-K-region epoxides, liver (rat), 73
 - multiple hepatic, inactivation, allylisopropylacetamide (rat), 299
 - suppression, mRNA, 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene (rat), 340
- Cytochrome P-450 reductase, NADPH, localization in liver (human), 189

D

- 3-Deazauridine, 2',3'-dideoxycytidine, metabolism, antiviral potency, 798
- Desferrioxamine, lipid peroxidation and, diquat-induced hepatic necrosis (rat), 417
- Dibenz(a,h)anthracene
 - phenols of, liver microsomal UDP-glucuronosyltransferase, regioselectivity (rat), 173
 - regio- and stereoselective metabolism, microsomal metabolites (rat), 710
- S-(1,2-Dichlorovinyl)-L-cysteine, induced renal mitochondrial toxicity, mechanism, 549
- 2',3'-Didehydro-2',3'-dideoxyribonucleosides, anti-HTLV-III and cytotoxic activity, 162
- 2',3'-Dideoxycytidine, regulation of metabolism, antiviral potency, pyrimidine nucleosides, 798
- E-Diethylstilbestrol, E,E-dienestrol and, interaction with tubulin, twisted ribbon structures, 731
- Digitalis, sensitivity, sodium and potassium-ATPase isoenzymes, heart (ferret), 201
- Dihydrofolate reductase, thymidylate synthase complex, purification, *Plasmodium falciparum*, 723
- Dihydropyridine
 - distribution in sympathetic neurons, multiple types of calcium channels (rat), 579
 - PN 200-110-binding sites, depolarization, myotubes (chick), 785
- γ -Diketones, 2,5-hexanedione-treated protein, formation and quantitation, imines/pyrroles/stable nonpyrrole adducts, 542
- Diquat, induced hepatic necrosis, lipid peroxidation, iron (rat), 417
- DNA
 - analysis of damage, dilute alkali-nuclease S₁, platinum analogues (human), 154
 - intracellular phosphorylation, anti-DNA virus agent, inhibited viral DNA synthesis, 524
 - ribonuclease-DNA complex, propidium binding, X-ray and fluorescence studies, 600
 - SV40, incorporation of 6-thioguanine, 606
 - synthesis by DNA polymerases, ara-5-aza-CTP, sequence-specific effects, 330
- Dopamine, receptors, *see* Receptors
- Dopamine B-hydroxylase, β -adrenergic receptors and, immuno cross-reactivity, 195
- Duodenum, smooth muscle, tachykinin-binding site, neurokinin A label (rat), 764

E

- Endopeptidase 24.11, irreversible photolabeling of enkephalinase, azidothiorphan (mouse), 587
- Endothelium-derived relaxing factor, cGMP, contractile responses of arteries, α -adrenoceptor stimulation (rat), 59
- Enzymes, *see also* specific type
 - xenobiotic metabolizing, parenchymal cells, liver (rat), 463
- Epidermal growth factor, receptor autophosphorylation capacity, de-

creased human birth weights, exposure to PCBs and PCDFs, 572

Epinephrine

- islet glucose utilization, α_2 -adrenoceptor stimulation (rat), 241
 - tight agonist binding, agonist competition binding curves, α_2 -adrenergic receptors, 65
- Epoxide hydrolase, activity, parenchymal cells, liver (rat), 463
- Epoxides, K-region and non-K-region, metabolism of chrysene, cytochrome P-450 isozymes (rat), 73
- Erythrohexestrol, interaction with tubulin, twisted ribbon structures, 731
- Erythroleukemia cells, compartmentation, α_2 -adrenergic receptors, 258
- ³H-Estradiol-17 β -(β -D-glucuronide)
 - binding to liver plasma membranes (rat), 511
 - multiple carriers for uptake, hepatocytes (rat), 519
- Estrogen
 - adrenergic-mediated production, inositol phosphates, uterus (rabbit), 663
 - regulation of hepatic sulfotransferase, activation, growth hormone (rat), 536
- Estrogenic drugs, interaction with tubulin, twisted ribbon structures, 731
- Ethanol
 - effect on β -adrenergic receptors, cerebral cortex (mouse), 217
 - effect on ionized calcium concentrates, synaptosomes, hepatocytes, 831
- Ethoxyresorufin O-deethylase, activity, parenchymal cells, liver (rat), 463

F

- Fluorine, positron emission tomography, androgens and progestins, probes for receptors, 391
- 5-Fluoro-2'-deoxyuridine, thymidine kinase-deficient herpes simplex virus, target, thymidylate synthase, 286
- Fluphenazine-mustard, pharmacological properties, 404
- Formate, S-adenosylmethionine and, reversal of nitrous oxide inhibition, formate oxidation (rat), 309
- Forskolin
 - acetylcholine and, calcium current, cardiac myocytes (frog), 639
 - calmodulin, inhibition of adenylate cyclase, 212
 - stimulation of adenylate cyclase, water-soluble analogues (rat), 133
- Funaltrexamine, covalent binding, μ opioid binding site (calf), 321

G

- Glioma cells, β -adrenergic receptor subtype, receptor gene product (mouse), 179
- Glucose, utilization, islets of of Langerhans, α_2 -adrenoceptor stimulation (rat), 241
- Glutamate, inositol phosphate metabolism, excitatory amino acids, striatal neurons, 364
- L-Glutamate, magnesium and, phencyclidine recognition sites, brain (rat), 820
- Glutathione, renal mitochondrial toxicity, S-conjugate-induced (rat), 549
- Glycosylation, mammalian α_1 -adrenergic receptors, N-linked oligosaccharides, 565
- Gold complexes, effect of auranofin, phospholipase C activity, 437
- Growth hormone, regulation of hepatic sulfotransferase, activation, N-hydroxyarylamide and N-hydroxyarylamine (rat), 536
- GTP-binding protein
 - cloned muscarinic receptor, expression in A9 L cells, 450
 - β subunit, structural properties (rabbit), 1
- Guanine nucleotide
 - agonist binding, muscarinic receptors, cismethyldioxolane (chick), 230
 - calmodulin, inhibition of adenylate cyclase, 212
 - pregnant rat myometrium, cAMP, heterologous regulations, 249

Guanosine monophosphate, cyclic, mediation, contractile responses of arteries, α -adrenoceptor stimulation (rat), 59
 Guanylate cyclase, mediation, platelet aggregation inhibition, carbon monoxide (human), 497

H

Haloperidol, σ receptor affinity, structural determinants (rat), 772

Heart

agonist binding, muscarinic receptors, cismethyldioxolane (chick), 230
 ligand effects, sodium/potassium-activated ATPase, membrane lipids (rat), 147
 myocytes, forskolin and acetylcholine effects (frog), 639
 sarcolemmal vesicles, voltage-dependent binding, nitrendipine, 278
 sodium and potassium-ATPase isoenzymes (ferret), 201

Hemin, cytochrome P-450 isozyme inactivation, allylisopropylacetamide (rat), 299

Hepatocytes

multiple carriers, uptake, ^3H -estradiol-17 β -(β -D-glucuronide) (rat), 519
 synaptosomes and, effect of ethanol, intracellular ionized calcium concentrates, 831

Hepatoma, phorbol ester-mediated redistribution, asialoglycoprotein receptor, 348

Herpes simplex virus

anti-DNA virus agent, intracellular phosphorylation, inhibited viral DNA synthesis, 524

(*E*)-5-(2-bromovinyl)-2'-deoxyuridine, cytostatic activity, mammary carcinoma, 410

thymidine kinase-deficient, 5-fluoro-2'-deoxyuridine, thymidylate synthase target, 286

2,4,5,2',4',5'-Hexachlorobiphenyl, 3-methoxy-4-aminoazobenzene or, co-induction, cytochrome P-450 isozymes in liver (rat), 206

3,4,5,3',4',5'-Hexachlorobiphenyl, 3-methylcholanthrene and, cytochrome P-450 2c suppression, mRNA, 340

2,5-Hexanedione, protein treatment, formation and quantitation, imines/pyrroles/stable nonpyrrole adducts, 542

Hippocampus, heterogeneity of α_1 -adrenergic receptors, chlorethylclonidine (rat), 505

Histamine

H2 receptor activation, mechanism, 557

phosphoinositide hydrolysis, developing brain (rat), 384

HL-60 cells, antiproliferative and cytotoxic effects, halogenated coral prostanoids, 530

HT29 cells, α -2 adrenoceptor turnover and metabolism, 646

HTLV-III, cytotoxic activity, 2',3'-didehydro-2',3'-dideoxyribonucleosides, 162

Human immunodeficiency virus, 2',3'-dideoxycytidine, metabolism, antiviral potency, 798

Hydrocarbons, aromatic

dibenz[*a,h*]anthracene, regio- and stereoselective metabolism (rat), 710

PCB and PCDF exposure, EGF-stimulated receptor autophosphorylation, human birth weights, 572

Hydroquinone, inhibition of pre-B cell maturation, bone marrow (mouse), 807

N-Hydroxyarylamide, *N*-hydroxyarylamine or, sulfotransferase regulation, growth hormone (rat), 536

7-Hydroxycoumarin, mitochondrial NADPH, effect of β -naphthoflavone (rat), 315

15-Hydroxyeicosanoic acid, φ -hydroxylation, lung microsomes, pregnancy (rabbit), 706

φ -Hydroxylation, 15-hydroxyeicosatetraenoic acid, lung microsomes, pregnancy (rabbit), 706

(*S*)-9-(3-Hydroxy-2-phosphorylmethoxypropyl)adenine, intracellular phosphorylation, inhibited viral DNA synthesis, 524

5-Hydroxytryptamine, see Serotonin

Hydroxyurea, 2',3'-dideoxycytidine, metabolism, antiviral potency, 798

I

Imines, formation in protein, 2,5-hexanedione treatment, 542

Immunohistochemistry, localization, NADPH-cytochrome P-450 reductase, liver (human), 189

Immunosuppression, lymphocyte ethoxyresorufin-*O*-deethylase activity, α -naphthoflavone antagonism, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 168

Immunotoxicity, inhibition of pre-B cell maturation, hydroquinone (mouse), 807

Inositol phosphates

adrenergic-mediated production, estrogen, uterus (rabbit), 663

heterogeneity of α_1 -adrenergic receptors, chlorethylclonidine (rat), 505

metabolism of, excitatory amino acids, striatal neurons, 364

receptor-mediated formation, calcium mobilization, 376

Iodination, vasopressin analogues, agonistic and antagonistic properties (rat), 369

(*E*)-5-(2-Iodovinyl)-2'-deoxyuridine 5'-diphosphate, (*E*)-5-(2-bromovinyl)-2'-deoxyuridine, thymidylate kinase, mammary carcinoma, 410

Iodovulone, halogenated coral prostanoids, antiproliferative and cytotoxic effects, leukemia cells, 530

Iron, lipid peroxidation and, diquat-induced hepatic necrosis (rat), 417

Islets of Langerhans, glucose utilization, α_2 -adrenoceptor stimulation (rat), 241

Isoproterenol

β -adrenergic receptors, effect of ethanol, cerebral cortex (mouse), 217

agonists and phorbol esters, desensitization, β -adrenergic receptors, 737

Isoquinolinesulfonamide derivatives, selective modulation, calcium-dependent myosin phosphorylation (human), 7

K

Kidney

cortex membrane vesicles, mitochondrial toxicity, *S*-conjugate-induced (rat), 549

vasopressin analogues, iodination, agonistic and antagonistic properties (rat), 369

L

Leukemia cells, antiproliferative and cytotoxic effects, halogenated coral prostanoids, *Clavularia viridis*, 530

Leukemia, P388, subline resistant to amasacrine, altered topoisomerase II function, 17

Leukotriene D₄, high affinity receptor antagonist, SKF 104353 (human, guinea pig), 223

Ligands

binding, effects of substance P, nicotinic acetylcholine receptors (*Torpedo*, rat, chick, goldfish), 625

effects on membrane lipids, sodium/potassium-activated ATPase, brain and heart enzymes (rat), 147

induced affinity changes, γ -aminobutyric acid receptor binding, brain (mouse), 266

Lipids

ligand effects, sodium, potassium-activated adenosine triphosphatase (rat), 147

peroxidation, iron and, diquat-induced hepatic necrosis (rat), 417

Liver

co-induction of cytochrome P-450 isozymes, 2,4,5,2',4',5'-hexachlorobiphenyl, 3-methoxy-4-aminoazobenzene (rat), 206

cytochrome P-450 isozyme inactivation, allylisopropylacetamide (rat), 299

diquat-induced necrosis, lipid peroxidation, iron (rat), 417

GTP-binding regulatory proteins, β subunit, structural properties (rabbit), 1

Liver—continued

- inhibitory monoclonal antibodies, cytochrome P-450 (rat), 615
 - K-region and non-K-region epoxides, chrysene metabolism, cytochrome P-450 (rat), 73
 - localization, NADPH-cytochrome P-450 reductase (human), 189
 - microsomal UDP-glucuronosyltransferase, phenols of benzo(a)pyrene, dibenz(a,h)anthracene (rat), 173
 - microsomes, *see* Microsomes
 - mitochondrial NADPH, effect of β -naphthoflavone (rat), 315
 - parenchymal cells, xenobiotic metabolizing enzymes (rat), 463
 - phenol sulfotransferase, structure-activity relationships (human, rat), 813
 - plasma membranes, binding, ^3H -estradiol-17 β -(β -D-glucuronide) (rat), 511
 - regulation of sulfotransferase, activation, growth hormone (rat), 536
 - suppression of cytochrome P-450 2c, mRNA, 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene, 340
 - vasopressin analogues, iodination, agonistic and antagonistic properties (rat), 369
 - vasopressin V₁ receptors, solubilization and reconstitution (rat), 34
- Locus coeruleus**, cellular mechanisms of opioid tolerance, single brain neurons (rat), 633
- Lung**
- high affinity receptor antagonist, SKF 104353, leukotriene D₄ (human, guinea pig), 223
 - microsomes, φ -hydroxylation of 15-hydroxyeicosanoic acid, pregnancy (rabbit), 706

M

- Magnesium**, L-glutamate and, phencyclidine recognition sites, brain (rat), 820
 - Malaria**, *Plasmodium falciparum*, purification, thymidylate synthase-dihydrofolate reductase, 723
 - Manoalide**, inhibition, phosphoinositide-specific phospholipase C (guinea pig), 587
 - Membrane potentials**, voltage-dependent nitrendipine binding, cardiac sarcolemmal vesicles, 278
 - Methemoglobinemia**, aniline-induced, contribution, aniline metabolites (rat), 423
 - Methionine**, formate and S-adenosylmethionine, reversal of nitrous oxide inhibition, formate oxidation (rat), 309
 - 3-Methoxy-4-aminoazobenzene**, 2,4,5,2',4',5'-hexachlorobiphenyl or, co-induction, cytochrome P-450 isozymes in liver (rat), 206
 - N-Methyl-D-aspartate**, metabolism of inositol phosphates, excitatory amino acids, striatal neurons, 364
 - 3-Methylcholanthrene**, 3,4,5,3',4',5'-hexachlorobiphenyl and, cytochrome P-450 2c suppression, mRNA, 340
- Microsomes**
- liver, localization, NADPH-cytochrome P-450 reductase (human), 189
 - lung, φ -hydroxylation of 15-hydroxyeicosanoic acid, pregnancy (rabbit), 706
 - metabolites, dibenz[a,h]anthracene, regio- and stereoselective metabolism (rat), 710
- Microtubules**, interaction of estrogenic drugs with tubulin, twisted ribbon structures, 731
- Mitochondria**
- effect of β -naphthoflavone, reducing equivalents, monoxygenation (rat), 315
 - renal toxicity, S-conjugate-induced (rat), 549
- Mitosis**, tubulin alkylation, effects of 6-benzyl-1,3-benzodioxole derivatives, 432
- Monoclonal antibodies**, inhibition of hepatic cytochromes P-450 (rat), 615
- Muscle cells**, α_1 -adrenergic receptor occupancy, 43
- Muscle, smooth**
- duodenal, neurokinin A label, tachykinin-binding site (rat), 764
 - heterogeneity of α_1 -adrenergic receptors, chloroethylclonidine (rat), 505

- phorbol ester-stimulated calcium flux (rat), 37
- Myelotoxicity**, inhibition of pre-B cell maturation, hydroquinone (mouse), 807
- Myocytes**, cardiac, forskolin and acetylcholine effects (frog), 639
- Myosin**
- calcium-dependent phosphorylation, selective modulation, isoquinolinesulfonamide derivatives (human), 7
 - light chain kinase, selective calmodulin inhibition, Ro 22-4839, 140
- Myotubes**, depolarization, PN 200-110-binding sites (chick), 785

N

- NADPH-cytochrome P-450 reductase**, localization in liver (human), 189
 - α -Naphthoflavone, antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin, ethoxyresorufin-O-deethylase activity, immunosuppression, 168
 - β -Naphthoflavone, effect on mitochondrial NADPH, liver (rat), 315
 - Neonate**, digitalis sensitivity, sodium and potassium-ATPase isoenzymes, heart (ferret), 201
 - Nephrotoxicity**, transport of cysteine conjugates, kidney cortex membrane vesicles (rat), 293
 - Neural hybrid cells**, N_i-coupled receptors, heterologous up-regulation, 669
 - Neuroblastoma cells**, μ and δ opioid receptor sites, 109
 - Neuroblastomas**, muscarinic receptor reserve, phosphoinositide turnover (guinea pig), 81
 - Neurokinin A**, tachykinin-binding site label, duodenal smooth muscle (rat), 764
 - Neuroleptics**, σ receptor affinity, structural determinants (rat), 772
- Neurons**
- brain, opioid tolerance, mechanism of (rat), 633
 - striatal, inositol phosphate metabolism, excitatory amino acids, 364
- Neurotoxicity**, 2,5-hexanedione-treated protein, formation and quantitation, imines/pyrroles/stable nonpyrrole adducts, 542
- Neurotransmitters**
- calmodulin role, cerebellar adenylate cyclase (rat), 127
 - cloned muscarinic receptor, expression in A9 L cells, 450
- Nitrendipine**, voltage-dependent binding, cardiac sarcolemmal vesicles, 278
- Nitrous oxide**, reversal of inhibition, formate and S-adenosylmethionine, formate oxidation (rat), 309
- Norepinephrine**
- heterogeneity of α_1 -adrenergic receptors, chloroethylclonidine (rat), 505
 - inhibited release, α_2 -adrenergic receptors, cerebral cortex (rat), 655
 - islet glucose utilization, α_2 -adrenoceptor stimulation (rat), 241

O

- Oligosaccharides**, N-linked, glycosylation, mammalian α_1 -adrenergic receptor, 565
 - Oocytes**, *Xenopus*, effect of avermectin B_{1a}, neuronal γ -aminobutyrate receptor channels (chick), 749
- Opioids**
- μ , binding site, funaltrexamine (calf), 321
 - σ receptor affinity, structural determinants (rat), 772
 - tolerance, mechanism of, single brain neurons (rat), 633
- Ouabain**, binding sites, pineal gland (rat), 792
- Oxotremorine**, muscarinic receptor heterogeneity, central nervous system (rat), 100
- Oxygen**, diquat-induced hepatic necrosis, lipid peroxidation, iron (rat), 417

P

- Paal-Knorr synthesis**, 2,5-hexanedione-treated protein, formation and quantitation, imines/pyrroles/stable nonpyrrole adducts, 542
- Parenchymal cells**, xenobiotic metabolizing enzymes, liver (rat), 463
- PC12 cells**, α -bungarotoxin binding, cholinergic function, 356

- Pertussis toxin, pregnant rat myometrium, cAMP, heterologous regulations, 249
- Phencyclidine, recognition sites in brain, interaction, L-glutamate and magnesium (rat), 820
- Phenol sulfotransferase, structure-activity relationships, phenolic substrates, liver (human, rat), 813
- Phenylhydroxylamine, aniline-induced methemoglobinemia (rat), 423
- Phorbol dibutyrate, redistribution, asialoglycoprotein receptor, 348
- Phorbol esters
 activators of protein kinase C, calcium regulation, anterior pituitary tumor cells (mouse), 488
 agonists and, desensitization, β -adrenergic receptors, 737
 calcium flux, vascular smooth muscle cells (rat), 37
- Phosphatidylinositol, high affinity leukotriene D₄ receptor antagonist, SKF 104353 (human, guinea pig), 223
- Phosphodiesterase, cAMP, response of S49 cells, agonists, 753
- Phosphoinositide
 hydrolysis, histamine-stimulated, developing brain (rat), 384
 inhibition of phospholipase C, manoolide (guinea pig), 587
 stimulation of breakdown in brain synaptoneurosomes, various agents, sodium influx activation (guinea pig), 479
 turnover, muscarinic receptor reserve, neuroblastomas (guinea pig), 81
- Phospholipase C
 effect of auranofin, 437
 muscarinic cholinergic receptors, propylbenzylcholine mustard, 443
 phosphoinositide-specific, inhibition by manoolide (guinea pig), 587
 platelet aggregation inhibition, carbon monoxide, mediation by guanylate cyclase (human), 497
- Phosphorylation
 intracellular, broad-spectrum anti-DNA virus agent, inhibited viral DNA synthesis, 524
 myosin, selective modulation, isoquinolinesulfonamide derivatives (human), 7
- Phosphotidylinositol, heterogeneity of α_1 -adrenergic receptors, chlorethylclonidine (rat), 505
- Photoaffinity labeling, radioligand crosslinking probe, adenosine receptor antagonist, 184
- Pineal gland, ouabain binding sites (rat), 792
- Pirenzepine, cloned muscarinic receptor, expression in A9 L cells, 450
- Pituitary, anterior, calmodulin, adenylate cyclase activation (rat), 743
- Pituitary tumor cells, activators of protein kinase C, calcium regulation (mouse), 488
- Placenta, decreased birth weight on exposure to PCBs and PCDFs, EGF-stimulated receptor autophosphorylation, 572
- Plasma membrane, liver, binding, ³H-estradiol-17 β -(β -D-glucuronide) (rat), 511
- Plasmodium falciparum*, purification, thymidylate synthase-dihydrofolate reductase, 723
- Platelets, aggregation inhibition, carbon monoxide, mediation by guanylate cyclase (human), 497
- Platinum analogues, analysis of DNA damage, dilute alkali-nuclease S₁ (human), 154
- PN 200-110, binding sites, depolarization, myotubes (chick), 785
- Polychlorinated biphenyls and dibenzofuran, decreased human birth weights after exposure, EGF-stimulated receptor autophosphorylation, 572
- Polymerases, DNA synthesis, ara-5-aza-CTP, sequence-specific effects, 330
- Polymorphism, murine Ah locus, mapping to chromosome 12 (mouse), 471
- Positron emission tomography, fluorinated androgens and progestins, molecular probes, receptors, 391
- Potassium
 adenosine triphosphatase, ligand effects, membrane lipids (rat), 147
 voltage-dependent nitrendipine binding, cardiac sarcolemmal vesicles, 278
- Potassium-ATPase
 ouabain binding sites, pineal gland (rat), 792
 sodium and, isoenzymes, heart (ferret), 201
- Potassium current, cellular mechanisms of opioid tolerance, single brain neurons (rat), 633
- Prazosin
 interactions of amiloride, α - and β -adrenergic receptors (rat), 53
 islet glucose utilization, α_2 -adrenoceptor stimulation (rat), 241
- Pregnancy, φ -hydroxylation of 15-hydroxyeicosanoic acid, lung microsomes (rabbit), 706
- Progestins, fluorinated androgens and, molecular probes for receptors, positron emission tomography, 391
- Propidium iodide, binding to ribonuclease-DNA complex, X-ray and fluorescence studies, 600
- Propranolol, islet glucose utilization, α_2 -adrenoceptor stimulation (rat), 241
- Propylbenzylcholine mustard, labeling of muscarinic cholinergic receptors, phospholipase C, adenylate cyclase, 443
- Prostacyclin, pregnant rat myometrium, cAMP, heterologous regulations, 249
- Prostaglandin E₁, agonists and phorbol esters, desensitization, β -adrenergic receptors, 737
- Prostaglandin E₂, pregnant rat myometrium, cAMP, heterologous regulations, 249
- Prostaglandins
 formation in brain, effects of tetrahydrocannabinol (guinea pig), 686
 φ -hydroxylation of 15-hydroxyeicosanoic acid, lung microsomes, pregnancy (rabbit), 706
- Prostanoids, halogenated coral, antiproliferative and cytotoxic effects, leukemia cells, 530
- Protein, 2,5-hexanedione-treated, formation and quantitation, imines/pyrroles/stable nonpyrrole adducts, 542
- Protein kinase C
 agonists and phorbol esters, desensitization, β -adrenergic receptors, 737
 calcium regulation, mechanisms, anterior pituitary tumor cells (mouse), 488
- Proton transfer model, molecular model for activation, serotonin receptor, 699
- Pyrimidine nucleosides, 2',3'-dideoxycytidine, metabolism, antiviral potency, 798
- Pyrroles, formation in protein, 2,5-hexanedione treatment, 542

Q

- Quisqualate, metabolism of inositol phosphates, excitatory amino acids, striatal neurons, 364

R

- Radioligands, photoaffinity crosslinking probe, adenosine receptor antagonist, 184
- Receptors
 σ , affinity, structural determinants (rat), 772
 acetylcholine, α -bungarotoxin binding, PC12 cells, 356
 adenosine
 calmodulin, inhibition of adenylate cyclase, 212
 new antagonist, radioligand crosslinking probe, 184
 α -adrenergic, *see* Adrenoceptors
 Ah, mapping to chromosome 12 (mouse), 471
 γ -aminobutyrate, effect of avermectin B_{1a}, *Xenopus* oocytes (chick), 749
 γ -aminobutyric acid, ligand-induced affinity changes, brain (mouse), 266
 μ and δ opioid, human neuroblastoma cells, 109
 asialoglycoprotein, phorbol ester-mediated redistribution, 348
 dopamine D₁ and D₂, response, cationic form of apomorphine (dog), 760
 gene product, β -adrenergic receptor subtype (mouse), 179
 histamine H₂, activation, mechanism, 557
 N-methyl-D-aspartate, phencyclidine recognition sites, L-glutamate and magnesium (rat), 820

Receptors—continued

muscarinic

- agonist binding, cismethyldioxolane (chick), 230
- cloned, expression in A9 L cells, 450
- heterologous up-regulation, neural hybrid cells, 669
- heterogeneity, central nervous system (rat), 91
- inositol phosphate formation, calcium mobilization, 376
- reserve, phosphoinositide turnover (guinea pig), 81
- muscarinic cholinergic, propylbenzylcholine mustard-labeling, phospholipase C or adenylate cyclase, 443
- N_i-coupled, heterologous up-regulation, neural hybrid cells, 669
- nicotinic acetylcholine
 - apophen and benactyzine, noncompetitive inhibitors, 678
 - barbiturate binding, allosteric regulatory site, 119
 - effects of substance P, ligand binding (*Torpedo*, rat, chick, goldfish), 625
 - interaction of benzomorphan opiate, acetylcholinesterase (*Torpedo*), 456
- opiate, heterologous up-regulation, neural hybrid cells, 669
- μ opioid, binding site, funaltrexamine (calf), 321
- progesterone, fluorinated androgens, positron emission tomography, 391
- serotonin, molecular model for activation, 699
- vasopressin, iodination, vasopressin analogues (rat), 369
- vasopressin V₁, solubilization and reconstitution, liver (rat), 34
- Respiration, regulation, adenosine and α_1 -adrenergic agonists, brown adipocytes (hamster), 26
- Rheumatoid arthritis, effect of auranofin, phospholipase C activity, 437
- Ribonuclease-DNA complex, propidium binding, X-ray and fluorescence studies, 600
- Rice oil disease, PCBs and PCDFs, decreased human birth weights, EGF-stimulated receptor autophosphorylation, 572
- RNA, incorporation of human breast cancer cells, effects, *cis*- and *trans*-tamoxifen isomers (human), 13
- RNA, messenger, suppression of hepatic cytochrome P-450 2c, 3,4,5, 3',4',5'-hexachlorobiphenyl, 3-methylcholanthrene, 340
- RNase A, ribonuclease-DNA complex, propidium binding, X-ray and fluorescence studies, 600
- Ro 22-4839, selective calmodulin inhibition, myosin light chain kinase, 140

S

- Sarcolemmal vessels, cardiac, voltage-dependent binding, nitrendipine, 278
- Saxitoxin, phosphoinositide breakdown in brain synaptoneurosome, sodium influx activation (guinea pig), 479
- S49 cells, response to agonists, cAMP phosphodiesterase activities, 753
- Serotonin, molecular model for activation of receptor, 699
- Sex-related differences, regulation of hepatic sulfotransferase, activation, growth hormone (rat), 536
- Simian virus 40, 6-thioguanine incorporation into DNA, 606
- SKF 104353, high affinity leukotriene D₄ receptor antagonist (human, guinea pig), 223
- Sodium
 - activation of influx by various agents, phosphoinositide breakdown, brain synaptoneurosome (guinea pig), 479
 - α -bungarotoxin binding in PC12 cells, cholinergic function, 356
 - potassium-ATPase and
 - isoenzymes, heart (ferret), 201
 - ligand effects, membrane lipids (rat), 147
- Sodium-ATPase, ouabain binding sites, pineal gland (rat), 792
- Sodium channels, voltage-sensitive, actions of toxin from *Conus striatus* (mouse), 691
- Steroid hormones, inhibition of hepatic cytochromes P-450, monoclonal antibodies (rat), 615
- Substance P, effects on ligand binding, nicotinic acetylcholine receptors (*Torpedo*, rat, chick, goldfish), 625
- Sulfotransferase, regulation by growth hormone, activation, *N*-hydrox-

yarylamide or *N*-hydroxyarylamine (rat), 536

- Superior cervical ganglion, distribution in sympathetic neurons, multiple types of calcium channels (rat), 579
- Sympathetic neurons, distribution, multiple types of calcium channels (rat), 579
- Synaptoneurosome, phosphoinositide breakdown in brain, various agents, sodium influx activation (guinea pig), 479
- Synaptosomes, hepatocytes and, effect of ethanol, intracellular ionized calcium concentrates, 831

T

- Tachykinin, binding site in duodenal smooth muscle, neurokinin A label (rat), 764
- Tamoxifen, *cis*- and *trans*- isomers, RNA incorporation, breast cancer cells (human), 13
- Taurocholate
 - ³H-estradiol-17 β -(β -D-glucuronide)
 - binding to liver plasma membranes (rat), 511
 - multiple carriers for uptake, hepatocytes (rat), 519
- Teniposide, subline to P388 leukemia, resistance to amsacrine, 17
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, lymphocyte ethoxyresorufin-*O*-deethylase activity, immunosuppression, α -naphthoflavone, 168
- Tetrahydrocannabinol, effects on prostaglandin formation (guinea pig), 686
- Tetrahydrofolate, formate and *S*-adenosylmethionine, reversal of nitrous oxide inhibition, formate oxidation (rat), 309
- Tetrodotoxin, phosphoinositide breakdown in brain synaptoneurosome, sodium influx activation (guinea pig), 479
- Thermogenesis, respiration regulation, adenosine and α_1 -adrenergic agonists, brown adipocytes (hamster), 26
- 6-Thioguanine, incorporation into SV40 DNA, 606
- Thromboxane, high affinity leukotriene D₄ receptor antagonist, SKF 104353 (human, guinea pig), 223
- Thymidylate synthase
 - activity of 5-fluoro-2'-deoxyuridine, herpes simplex virus, 286
 - cytostatic activity, (E)-5-(2-bromovinyl)-2'-deoxyuridine, mammary carcinoma, 410
- Thymidylate synthase-dihydrofolate reductase complex, purification, human malaria parasite, *Plasmodium falciparum*, 723
- Topoisomerase II, subline of P388 leukemia, resistance to amsacrine, 17
- Triethylphosphine gold chloride, effect of auranofin, phospholipase C activity, 437
- Tubulin
 - alkylation, effects of 6-benzyl-1,3-benzodioxole derivatives, 432
 - interaction with estrogenic drugs, twisted ribbon structures, 731

U

- UDP-glucuronosyltransferase, regioselectivity, phenols of benzo(*a*)pyrene, dibenz(*a,h*)anthracene (rat), 173
- Uterus
 - adrenergic-mediated production, inositol phosphates, estrogen (rabbit), 663
 - pregnant rat myometrium, cAMP, heterologous regulations, 249

V

- Vasopressin, V₁ receptors, solubilization and reconstitution, liver (rat), 34
- Vasopressin analogues, iodination, agonistic and antagonistic properties (rat), 369

Y

- Yohimbine, compartmentation, α_2 -adrenergic receptors, human erythroleukemia cells, 258
- Yucheng, EGF-stimulated receptor autophosphorylation, decreased human birth weights, exposure to PCBs and PCDFs, 572

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Bauge, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Editor: **Eva King Killam, PhD**

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. **Monthly**

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals

Editor: **Vincent G. Zannoni, PhD**

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. The areas covered are • pharmacokinetics, pharmacodynamics, and mechanisms • genetic, nutritional, or hormonal factors affecting the biological fate of chemicals • toxicological consequences of xenobiotic metabolism. **Bimonthly**

PHARMACOLOGICAL REVIEWS

Editor: **James A. Bain, PhD**

PHARMACOLOGICAL REVIEWS is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. **Quarterly**

MOLECULAR PHARMACOLOGY

Editor: **William A. Catterall, PhD**

The papers published in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. **Monthly**




Order free by phone. Call 1-800-638-6423 from anywhere in the U.S. except AK. MD residents, call 528-4105 collect.



Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203
266 Fulham Road
London SW10 9EL England



YES! Enter my subscriptions to the following:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscriptions today!

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (monthly)

☐ Individual: \$140/yr ☐ Institutions: \$220/yr
(Please add \$30.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

DRUG METABOLISM AND DISPOSITION (bimonthly)

☐ Individual: \$60/yr ☐ Institutions: \$95/yr
(Please add \$10.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

MOLECULAR PHARMACOLOGY (monthly)

☐ Individual: \$75/yr ☐ Institutions: \$165/yr
(Please add \$15.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

PHARMACOLOGICAL REVIEWS (quarterly)

☐ Individual: \$35/yr ☐ Institutions: \$70/yr ☐ In-training: \$25/yr
(Please add \$10.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Payment options:

☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card #

signature/P.O.#

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1988.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. *Residents, fellows, interns, and students*, when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

name

address

city state zip

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203

266 Fulham Road
London SW10 9EL, England

ASPETAD 1033 88



An important resource for everyone
involved in research on the
metabolism of drugs and chemicals

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals


Editor: **Vincent G. Zannoni, PhD**, University of Michigan,
Ann Arbor, Michigan

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. All papers are referred to ensure a high standard of publication. The areas covered are:

- pharmacokinetics
- pharmacodynamics
- genetic, nutritional, and hormonal factors affecting the biological fate of chemicals
- toxicological consequences of xenobiotic metabolism

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in designing drugs and all biochemists involved with drug metabolism.

Bimonthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

Drug Metabolism and Disposition (bimonthly)

☐ Individual: \$60/yr ☐ Institutions: \$95/yr

(Please add \$10.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Payment options:

☐ Check enclosed
☐ VISA

☐ Bill me

☐ MasterCard

☐ American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, *in US dollars only*. Rates valid for orders received before October 31, 1988.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. *Residents, fellows, interns, and students*, when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203

266 Fulham Road
London SW10 9EL, England

DMDAD 1039 88



INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. William A. Catterall, Department of Pharmacology, SJ-30, University of Washington, Seattle, WA 98195.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$75.00; institutional, \$165.00, single copy, \$16.00. FOREIGN: personal, \$90.00; institutional, \$180.00; single copy, \$19.00. JAPAN: personal, \$123.00; institutional, \$213.00 (includes air freight). (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Japanese Yen price is available from our sole agent: USACO Corporation, 13-12 Shimbashi 1-Chome, Minato-Ku, Tokyo 105, Japan, telephone 03-502-6471. Subscriptions in South Korea are available only through our sole agent in Korea: Korea-America Medical Books Co., Ltd. (KAMBOOK), 209 Yun kun-dong, Chongro-ku, Seoul, Korea (telephone: 745-3151; telex: K25211 KAMBC; FAX: 745-3153). All subscriptions to South Korea will be shipped by air freight after January 1, 1988. There is an air freight surcharge of \$12.00 over the regular subscription rate for this journal in South Korea to partially compensate for air freight costs.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions and renewals are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD. 21202 U. S. A.

BIOLOGY RESEARCH SCIENTISTS

THE LILLY RESEARCH LABORATORIES, A Division of Eli Lilly and Company is expanding its effort in Connective Tissue, Pulmonary and Leukotriene Research.

In keeping with our long-standing commitment to research excellence, it is our intent to attract PhD. Scientists with post-doctoral experience and demonstrated research accomplishments. Senior Scientists would be expected to develop their own research programs that would complement the endeavors of other scientists. Opportunities are present for collaboration with pharmacologists, biochemists, cell biologists, molecular biologists, immunologists, pathologists and medicinal chemists.

Connective Tissue Research

(Bone Biology and Inflammatory Disease)

Bone Biology (Osteoporosis) (N₁)—We are seeking a Senior Scientist with a PhD. in Pharmacology/Cellular and Developmental Biology/Biochemistry to study factors influencing bone/cartilage differentiation, and to seek new therapeutics in osteoporosis, associated bone disorders and osteoarthritis. Experience with *in vivo* models is essential. The scientist would join others expert in biochemistry, cellular and molecular biology and pathology.

Inflammatory Disease (N₂)—A Senior Scientist with a PhD. in Pharmacology/Cell Biology/Biochemistry is needed to participate in a research program directed toward the understanding of inflammatory disease mechanisms and the development of novel agents for therapeutic intervention. Expertise in the role of macrophages and/or polymorphonuclear leucocytes in the inflammatory process is essential and will complement existing expertise in pharmacology, immunology, biochemistry, and pathology.

Pulmonary and Leukotriene Research

(Phospholipid & Biochemical Pharmacology)

Phospholipid Biochemistry (N₃)—A Senior Scientist with a PhD. in Pharmacology/Cell Biology/Biochemistry will participate in a research program directed toward understanding the roles of cellular phospholipids in the generation of disease associated mediators (e.g. leukotrienes, thromboxanes, prostalandins, and platelet activating factor) and the development of novel inhibitors of the generation of these mediators. Experience with whole cell enzyme assays is desirable. Disease targets include asthma, allergy and inflammation.

Biochemical Pharmacology (N₄)—A Senior Scientist with a PhD. in Pharmacology/Biochemistry/Cell Biology experienced in cellular aspects of the arachidonic acid cascade is needed to study the role of leukotrienes in pulmonary diseases. This individual will collaborate with scientists studying the role of leukotrienes in myocardial infarction and ischemia, stroke, GI disease, inflammatory disease, skin diseases and their role in immune function.

Scientists with a doctoral degree and post-doctoral experience in the aforementioned research areas are encouraged to send a curriculum vitae and indication of their specific area of interest [phospholipid (N₃), bone biology (N₁), etc.] to:



John W. Crooks, Manager, College Relations (SBR)
Eli Lilly and Company, Lilly Corporate Center
Indianapolis, Indiana 46285

Equal Opportunity Employer